Schmidt, Teresa
Meyerhoff, Nina
Meller, Sebastian
Twele, Friederike
Charalambous, Marios
Berk, Benjamin A.
Law, Tsz H.
Packer, Rowena M. A.
Zanghi, Brian
Pan, Yuanlong
Fischer, Andrea
Volk, Holger A.
Funding for this research was provided by:
Morris Animal Foundation
Biotechnology and Biological Sciences Research Council (BB/P001874/1, BB/J012491/1)
American Kennel Club Canine Health Foundation (2252)
Article History
Received: 8 December 2023
Accepted: 7 May 2024
First Online: 24 May 2024
Declarations
:
: The animal study protocol was reviewed and approved by the thesis committee of the University of Veterinary Medicine Hannover and was conducted following the University guidelines. In the current study, data from former epilepsy trials were used. These animal study protocols were approved by the local Ethics and Welfare Group (EWG), the Clinical Research Ethical Review Board (CRERB) and the Lower Saxony State Office for Consumer Protection and Food Safety (Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit [LAVES], Oldenburg, Germany) (URN 2011 1132; URN 2016 1558; approval number 33.8-42502-05-19A469, 25.11.2019). Written informed consent was obtained from the owners for the participation of their animals in this study.
: Not applicable.
: BB was employed by company BrainCheck.Pet® and BZ and YP were employed by company Nestlé Purina PetCare®. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funders of the former epilepsy trials had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
: Preliminary results of the current study were presented at the following conferences: 1<sup>st</sup> Texas A&M Neural-Gut Axis Symposium 2024 (awarded with the 3<sup>rd</sup> poster price).